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Clinical feasibility of umbilical cord 
tissue-derived mesenchymal stem cells 
in the treatment of multiple sclerosis
Neil H. Riordan1,2*, Isabela Morales2, Giselle Fernández1, Nicole Allen3, Neal E. Fearnot3, Michael E. Leckrone4, 
Dedra Jones Markovich3, Darla Mansfield3, Dorita Avila2, Amit N. Patel5, Santosh Kesari6 
and Jorge Paz Rodriguez1
Abstract 
Background: Multiple sclerosis (MS) is a progressively debilitating neurological condition in which the immune 
system abnormally erodes the myelin sheath insulating the nerves. Mesenchymal stem cells (MSC) have been used in 
the last decade to safely treat certain immune and inflammatory conditions.
Methods: A safety and feasibility study was completed on the use of umbilical cord MSC (UCMSC) as a treatment 
for MS. In this 1-year study, consenting subjects received seven intravenous infusions of 20 × 106 UCMSC over 7 days. 
Efficacy was assessed at baseline, 1 month and 1 year after treatment, including magnetic resonance imaging (MRI) 
scans, Kurtzke Expanded Disability Status Scale (EDSS), Scripps Neurological Rating Scale, Nine-Hole Peg Test, 25-Foot 
Walk Test, and RAND Short Form-36 quality of life questionnaire.
Results: Twenty subjects were enrolled in this study. No serious adverse events were reported. Of the mild AEs 
denoted as possibly related to treatment, most were headache or fatigue. Symptom improvements were most 
notable 1 month after treatment. Improvements were seen in EDSS scores (p < 0.03), as well as in bladder, bowel, and 
sexual dysfunction (p < 0.01), in non-dominant hand average scores (p < 0.01), in walk times (p < 0.02) and general per-
spective of a positive health change and improved quality of life. MRI scans of the brain and the cervical spinal cord 
showed inactive lesions in 15/18 (83.3%) subjects after 1 year.
Conclusions: Treatment with UCMSC intravenous infusions for subjects with MS is safe, and potential therapeutic 
benefits should be further investigated.
Trial registration ClinicalTrials.gov NCT02034188. Registered Jan 13, 2014. https ://clini caltr ials.gov/ct2/show/NCT02 
03418 8
Keywords: Multiple sclerosis, Umbilical cord stem cells, Stem cell therapy, Multiple sclerosis treatment, Mesenchymal 
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Background
Multiple sclerosis (MS) is an immune-mediated inflam-
matory disease in which the immune system progres-
sively destroys its own myelinated axons in the central 
nervous system, in episodes lasting from a few months to 
many years in duration. The eventual demyelination and 
axonal degeneration can cause serious and debilitating 
motor, sensory, balance and cognitive problems, disabil-
ity, serious complications, and negatively impact quality 
of life [1–3].
While there is no known cure for MS, up to 82% of 
costs incurred by MS patients are spent on drugs [4]. 
Treatments available include steroids for temporary flare-
ups, disease-modifying drugs, and drugs targeting spe-
cific symptoms. While these may reduce the frequency 
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myelin or nerve regenerative capability to restore the 
cumulative damage already in place [5].
Mesenchymal stem cells (MSC) derived from bone 
marrow, adipose, or other sources can exert inhibitory 
effects on immune-mediated disease states [6–10]. In 
particular, MSC derived from umbilical cord (UC) Whar-
ton’s Jelly possess a high proliferative and expansive abil-
ity, an enhanced therapeutic activity compared to other 
MSC [11–14], and superior production of growth fac-
tors that stimulate secretions responsible for therapeutic 
potential [15].
The safety of MSC therapy for MS has been demon-
strated in several trials [16–20]. We reported three sub-
jects treated with MSC and stromal vascular fraction 
with no adverse effects; all showed clinical improvements 
in cognitive and motor function and presented no new 
lesions on magnetic resonance imaging (MRI) [21]. More 
recently, trials with placenta-derived MSC [22], or with 
intravenous UCMSC [23] reported few mild or mod-
erate adverse effects, as well as some improvement in 
Expanded Disability Status Scale (EDSS) scores.
In this study, we sought to determine the safety and the 
efficacy of allogeneic UCMSC treatment in subjects with 
MS.
Methods
This open-label, single-arm, single-center phase 1/2 
study was designed to assess the safety and efficacy of 
the intravenous administration of UCMSC for the treat-
ment of MS. The study was approved by the Panamanian 
Institutional Review Board (Comité Nacional de Ética 
de la Investigación) and registered in the ClinicalTrials.
gov database (NCT02034188). The study sponsor was 
Translational Biosciences. All treatments were adminis-
tered at the Stem Cell Institute in the Republic of Pan-
ama, under Protocol Number TBS-UCMSC-001. Safety 
was defined as absence of treatment-associated adverse 
events at 1, 3 months, and 1 year post treatment. Efficacy 
was assessed with traditional MS evaluation instruments 
and a quality of life questionnaire at follow-up intervals, 
as detailed in the “Treatment protocol” section.
Subjects were enrolled under the following criteria: 
men or non-pregnant women ages 18–55 diagnosed 
according to revised McDonald criteria [24] for clini-
cally-defined MS; an EDSS score of 2.0–7.0 assessed at 
least 3 months after the last acute attack of MS; willing-
ness to keep a weekly diary and undergo observation for 
1 year, and provision of documented health insurance in 
their home country. Enrolled subjects were not required 
to refrain from taking other medications or supplements 
prior to study entry.
Subjects were excluded if they presented active prolif-
erative retinopathy, poorly controlled diabetes mellitus 
(glycosylated hemoglobin HbA1C > 8.5%), renal insuf-
ficiency (Creatinine > 2.5  mg/dL) or failure, infection 
(white blood cell count of > 15,000 K/cumm and/or tem-
perature > 38 °C), history of organ transplant, previous or 
active malignancy, or cardiovascular conditions. All par-
ticipants provided written informed consent before study 
participation.
Treatment protocol
Complete medical history, medication history, and list of 
concomitant medications were collected from all subjects 
prior to any treatment. Subjects also underwent a com-
plete physical examination, vital signs (heart rate, respira-
tory rate, temperature, and systolic and diastolic blood 
pressure), a 12-lead electrocardiogram (ECG), and labo-
ratory testing (complete blood count, serum chemistry) 
at baseline. MS diagnosis was confirmed according to the 
revised McDonald criteria. Enrolled subjects received 
140 × 106 UCMSC intravenously over the course of seven 
visits (20 × 106 UCMSC/day) separated by 1–4  days. 
At each treatment visit, subjects were assessed for any 
adverse events experienced since their last visit, received 
a physical examination (vital signs pre- and post- infu-
sion), and were reviewed for adverse events throughout 
the visit.
Follow-up visits, scheduled at 1, 3  month and 1  year 
post-treatment, could take place at either the Stem Cell 
Institute or near the subjects’ place of residence, overseen 
by a licensed medical professional. At all follow-up vis-
its, any adverse events experienced since last visit were 
reviewed, and subjects received a physical examination, 
laboratory tests and a 12-lead ECG. Any concomitant 
medications were reviewed.
Adverse events were reported in terms of their sever-
ity (mild, moderate, severe), relatedness (definitely, 
probably, possibly, not likely and unrelated), action 
taken (none, adjustment, interruption or discontinu-
ation of treatment dosage), medications or therapy 
taken (drug therapy, non-drug therapy, or none), and 
outcome (not recovered/resolved, recovered/resolved, 
recovering/resolving, recovered/resolved with 
sequelae, fatal and unknown). Efficacy parameters 
were assessed at baseline, at 1  month, and at 1  year, 
and included time point measures for the Kurtzke 
Expanded Disability Status Scale (EDSS), the Scripps 
Neurological Rating Scale (SNRS), the Nine-Hole Peg 
Test (9HPT), the 25-Foot Walk Test (25FWT), and the 
RAND Short Form-36 (SF-36) quality of life (QOL) 
questionnaire.
Gadolinium-enhanced MRI scans of the brain and 
cervical spinal cord were taken at baseline and 1  year 
after treatment, and were examined by a single inde-
pendent radiologist blinded to the intervention.
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UCMSC preparation and culture
UCMSC in this study were produced by MediStem 
Panama Inc. UCMSC were isolated from afterbirth tis-
sue obtained after full-term, healthy births, donated by 
consenting mothers. After screening for infection and 
contamination, UCMSC were obtained from enzymatic 
digestion of Wharton’s Jelly tissue after a primary cul-
ture process at 37  °C, 5% CO2 during 24 h. Cells were 
expanded using alpha-MEM (Gibco Life Technolo-
gies, Grand Island, NY), supplemented with 10% FBS 
(USFDA approved, Gibco Life Technologies, Grand 
Island, NY), and 4  mM GlutaMax (Gibco Life Tech-
nologies, Grand Island, NY) in triple flasks under nor-
moxic conditions. Cells were assessed between passages 
two and three for meeting MSC criteria and absence 
of contamination. Each enzymatic digestion step was 
considered to be a passage. Cells were harvested after 
5 passages (3–4  weeks after initiation of primary cul-
ture). MediStem Panama used the minimal criteria 
established by the Mesenchymal and Tissue Stem Cell 
Committee of International Society for Cellular Ther-
apy [25]. Each lot was tested for sterility (fungus, myco-
plasma, aerobes and anaerobes), endotoxin level below 
3  EU/ml, and viability after thawing higher than 75%. 
The approved cells expressed surface molecules CD105, 
CD73 and CD90, and lacked expression of CD45 and 
CD34, as determined by flow cytometry. UCMSC were 
also tested for differentiation into adipocytes, chondro-
blasts, and osteoblasts in vitro using  StemPro® media, 
and stained with oil red, alcian blue and alizarin red, 
respectively. Approved cells were suspended in a dex-
trose and saline solution for subsequent administration.
Statistical analysis
SYSTAT version 13.1 (SYSTAT Software Inc., San Jose, 
CA, USA) was used to analyze the data. Differences 
between baseline and follow-up scores were examined 
using paired t-tests, with Bonferroni and Dunn-Sidak 
corrections where applicable. A p-value of p < 0.05 was 
considered significant.
Results
Twenty subjects with MS provided informed con-
sent and were enrolled into this feasibility study from 
October 10, 2014 to February 18, 2015. Mean age of 
enrollees was 41.15 (SD = 9.29) years; 60% (12/20) 
were female (Table  1). Enrolled subjects were of mul-
tiple international origins, including the Republic of 
Panama. The mean disease duration of enrollees was 
7.7  years. Fifteen subjects (75%) had a diagnosis of 
relapsing–remitting MS, four (20%) with primary pro-
gressive MS, and one (5%) with secondary progressive 
MS. Eleven subjects (55%) required ambulation assis-
tance (wheelchair, walker, or cane) at baseline. Five 
subjects (25%) did not take any MS-specific medication 
over the course of the study, 10 (50%) continued taking 
their usual MS medications, one (5%) began using MS-
specific medication during follow-up, and four (20%) 
reduced their intake of MS-specific medication during 
follow-up.
All subjects received all of the infusions specified by 
the treatment protocol, and attended the 1- and 3-month 
visits. Nineteen subjects were followed for 1  year: the 
1-year visit was completed for 17/20 subjects, two sub-
jects partially completed the 1-year requirements. One 
subject was lost to follow-up.
All subjects survived the study, and there were no 
reported serious adverse events (AEs). None of the 
reported AEs (Table 2) required adjustment, interruption 
Table 1 Demographics of subjects in the study
Demographic N = 20
Age (years)
 Mean (SD) 41.15 (9.29)
 (Range) (24–55)
Gender
 Male 40% (8/20)
 Female 60% (12/20)
Diagnosis
 Relapsing remitting MS 75% (15/20)
 Primary progressive MS 20% (4/20)
 Secondary progressive MS 5% (1/20)
Disease duration (years)
 Mean = 7.7
  < 3 25% (5/20)
  4–6 25% (5/20)
  7–9 30% (6/20)
  10–12 10% (2/20)
  16–18 5% (1/20)
  19–21 5% (1/20)
Ambulation status
 Wheelchair 55% (11/20)
 Walker 20% (4/20)
 Bilateral cane 5% (1/20)
 Unilateral cane 20% (4/20)
 No assistance 45% (9/20)
Origin
 White/Caucasian 65% (13/20)
 African Descent 10% (2/20)
 Middle Eastern 5% (1/20)
 Other (1 each Hispanic, Brazilian, Panamanian, and multi-
racial: Hispanic/White/Native American)
20% (4/20)
Page 4 of 12Riordan et al. J Transl Med  (2018) 16:57 
or discontinuation of treatments. There were six moder-
ate AEs, and 66 mild AEs. No AEs were ongoing at the 
1-year follow-up visit. No AEs were classified as defi-
nitely related to study treatment. The most commonly 
reported AEs were headache (18 mild and one moder-
ate), and fatigue (19 mild), classified as possibly related to 
treatment.
EDSS scores were recorded at baseline and 1  month 
post-treatment for all subjects; scores at 1  year were 
available for 17 of 20 subjects (Fig. 1). At baseline, EDSS 
scores ranged from 2.5–7.0, with a mean score of 5.23 
(SD = 1.50). At 1  month, the mean score decreased to 
4.75 (SD = 2.00), a mean reduction of 0.48 (SD = 0.85) or 
about one category. Scores reduced further at the 1-year 
time point, to 4.62 (SD = 2.72), a mean reduction of 0.68 
(SD = 1.49), a little more than one category. Differences 
were statistically significant at 1  month (p < 0.03), and 
1 year (p < 0.04) when compared to baseline.
SNRS scores were recorded at baseline and 1  month 
post-treatment for all subjects; scores at 1  year were 
recorded for 17 of 20 subjects (Table 3). The SNRS total 
mean score rose slightly from 75.0 (SD = 11.9) at base-
line to 75.5 (SD = 16.5) at 1  month post-treatment, and 
decreased to 73.5 (SD = 19.5, N = 17) 1  year post-treat-
ment. A statistically significant improvement (p < 0.01) 
was seen for the bladder/bowel/sex dysfunction category 
at 1 month from the baseline assessment (Fig. 2). A statis-
tically significant worsening was seen in the study group 
Table 2 Reported adverse events
Event Count Severity Relatedness
Mild Moderate Severe Not related Not likely Possibly Probably Definitely
Headache 19 18 1 0 1 1 16 1 0
Fatigue 19 19 0 0 0 2 17 0 0
Cardiovascular 8 8 0 0 2 2 4 0 0
Injury/accident 8 6 2 0 8 0 0 0 0
Gastrointestinal 4 2 2 0 1 2 1 0 0
Musculoskeletal 4 4 0 0 1 3 0 0 0
Infection 3 3 0 0 2 0 1 0 0
Feelings/sensations 3 3 0 0 0 2 1 0 0
Dizziness 2 2 0 0 1 1 0 0 0
Gynecological 1 0 1 0 1 0 0 0 0
Skin disorder 1 1 0 0 0 1 0 0 0
Total 72 66 6 0 17 14 40 1 0
Fig. 1 Kurtzke Expanded Disability Status Scale (EDSS) mean scores. Possible scores range from 0 (no disability) to 10 (death resulting from MS 
complications). Scores from 1.0 to 4.5 indicate an ability to walk without any aid, and scores from 5.0 to 9.5 indicate an impairment to walking. 
N = 20 at 1 month (same as baseline), N = 17 at 1 year. Statistically significant changes between time points are indicated with their p-values. Error 
bars represent standard deviations
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in four categories compared to baseline: visual acuity 
at 1  month (p < 0.02) and 1  year (p < 0.03), right upper 
extremity motor function at 1 year (p < 0.02), right lower 
extremity sensory function at 1  month (p < 0.03) and 
1  year (p < 0.01), and left lower extremity sensory func-
tion at 1 month (p < 0.01).
The 9HPT was recorded for all subjects at baseline 
and 1  month post-treatment; scores were available for 
19 of 20 subjects at 1 year (one lost to follow-up). Over-
all, subjects saw improvements in their scores. Statisti-
cally significant improvements from baseline were seen 
in non-dominant hand scores for both best (p < 0.01) 
and average (p < 0.02) times at the 1-month assessment 
(Fig.  3). The best score for the non-dominant hand was 
37.56  s at baseline, 32.49 at 1  month (5.1  s improve-
ment), and 31.55 at 1 year (6.0 s improvement). The aver-
age mean score for the non-dominant hand was 40.80 s 
at baseline, 35.01 at 1 month (a 5.8 s improvement), and 
34.09 (a 6.7 s improvement).
For the 25FWT, subjects were categorized into one 
of four categories, based on their need for assistance to 
complete the test (in order of increasing need): no assis-
tance; cane; walker, and wheelchair. While scoring guid-
ance for the 25FWT directs to use the average of the two 
completed trials, the minimum time was also analyzed 
to enable inclusion of any/all subject(s) who completed 
at least one full trial. At baseline, all 20 subjects were 
available for the 25FWT, and 19 subjects were available 
at 1 month (one did not take the test). At 1 year, results 
were recorded for 17 subjects (two did not take the test; 
and one was lost to follow up). Some subjects were una-
ble to complete one or both trials due to ambulation sta-
tus (two were wheelchair-bound at baseline, one at the 
1-month and at 1-year follow-ups), or fatigue (one sub-
ject was fatigued at the 1-year follow-up).
At baseline, average time for the 25FWT Trial 1 was 
17.43  s and 17.51  s for Trial 2 (Table  4). Overall mean 
time was 17.47 s, and average minimum time was 15.85 s. 
One month after treatment, average walk time for Trial 
2 improved by 6.01  s, but average time for Trial 1 took 
longer than baseline, as did overall mean time, and aver-
age minimum time. At 1 year, all walk times were reduced 
when compared to baseline. Since not all subjects com-
pleted both trials of the 25FWT at a given time point, 
and not all subjects completed all follow-ups, statisti-
cal comparisons between baseline and follow-up scores 
could not include all subjects. Twelve subjects completed 
Trial 2 of the 25FWT at the three follow-up time points 
Table 3 Scripps neurological rating system (SRNS) component scores
*Statistically significant change, p < 0.05
SNRS component Baseline 1 month 1 year
Mentation and mood (normal = 10) 8.4 (2.28) 9.4 (1.57) 9.3 (1.69)
Visual acuity (normal = 5)* 4.9 (0.45) 4.2* (1.35) 4.2* (1.24)
Visual fields (normal = 6) 5.7 (0.73) 5.6 (1.05) 5.6 (0.79)
Eye movements (normal = 5) 4.8 (0.62) 4.8 (0.62) 4.8 (0.66)
Nystagmus (normal = 5) 5.0 (0.00) 4.8 (0.62) 4.9 (0.49)
Lower cranial nerves (normal = 5) 5.0 (0.00) 4.9 (0.45) 5.0 (0.0)
Motor function R upper extremity (normal = 5)* 4.8 (0.62) 4.5 (0.89) 4.1* (1.44)
Motor function L upper extremity (normal = 5) 4.3 (0.98) 4.4 (1.14) 4.1 (1.44)
Motor function R lower extremity (normal = 5) 3.2 (1.66) 2.6 (1.82) 2.4 (1.91)
Motor function L lower extremity (normal = 5) 2.7 (1.81) 2.7 (2.03) 2.7 (2.23)
DTR upper extremity (normal = 4) 3.6 (0.95) 3.3 (1.22) 3.6 (0.79)
DTR lower extremity (normal = 4) 2.4 (1.35) 2.1 (1.62) 2.3 (1.61)
Babinski sign L side (absent = 2) 0.6 (0.94) 0.9 (1.02) 0.7 (0.99)
Babinski sign R side (absent = 2) 0.8 (1.01) 0.8 (1.01) 0.5 (0.87)
Sensory R upper extremity (normal = 3) 3.0 (0.00) 2.7 (0.47) 2.8 (0.56)
Sensory L upper extremity (normal = 3) 3.0 (0.00) 2.6 (0.50) 2.8 (0.56)
Sensory R lower extremity (normal = 3)* 2.9 (0.31) 2.5* (0.51) 2.5* (0.72)
Sensory L lower extremity (normal = 3) 2.9 (0.31) 2.5* (0.51) 2.5 (0.80)
Cerebellar signs upper extremity (normal = 5) 4.0 (1.52) 4.0 (1.52) 4.1 (1.60)
Cerebellar signs lower extremity (normal = 5) 2.9 (1.46) 3.6 (1.87) 3.4 (1.77)
Gait trunk and balance (normal = 10) 5.1 (2.74) 5.6 (3.17) 4.6 (3.69)
Bladder, bowel, and/or sexual dysfunction (normal = 0)* − 4.7 (2.52) − 2.7* (2.89) − 3.1 (3.31)
Total SNRS 75.0 (11.90) 75.5 (16.54) 73.5 (19.52)
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(baseline, 1  month and 1  year), with a statistically sig-
nificant reduction (p < 0.02) in walk times found between 
baseline and 1 month (Fig. 4).
Some subjects changed ambulatory status at the time 
of the 25FWT at the 1-month visit: two subjects reduced 
their dependence upon assistive devices (one from wheel-
chair to walker, one from walker to cane); one became 
more dependent (from no assistance to a cane). At the 
1-year visit, two subjects reduced their dependence upon 
assistance devices from baseline to 1-year visit (one from 
wheelchair to walker, one from walker to cane to no 
assistance); two increased dependency (one from unilat-
eral cane to walker, one from no assistance to cane). One 
of the subjects, wheelchair-bound at baseline and thus 
unable to complete the test then, was able to complete it 
at the 1-month and 1-year follow-ups.
Scores for the RAND SF-36 test were recorded for all 
subjects at baseline and 1 month, and for 17 of 20 sub-
jects at 1 year post-treatment. Overall, subjects reported 
improvements in their health during the study. Total 
QOL scores increased over baseline for 15 subjects at 
the 1  month follow up visit, while only five decreased. 
At 1  year, total QOL score improved over baseline for 
11 subjects, while six decreased (Fig. 5). At 1 month and 
1 year, more than half of the subjects reported their con-
dition as better or the same on all scale scores (Table 5). 
At 1 month, more than 50% of subjects reported improve-
ments on five of the eight scale scores (role limitations-
physical, energy/fatigue, emotional well-being, social 
functioning, and general health), as well as health change; 
45% (9/20) of subjects reported improvements in the 
pain scale, and 35% (7/20) of subjects reported improve-
ments in their physical functioning and role limitations-
emotional. At 1 year, more than half of subjects reported 
feeling better in five of the eight scales (physical function-
ing, role limitations-physical, energy/fatigue, emotional 
wellbeing, and general health), as well as health change; 
47% (8/17) reported improvements in their social func-
tioning, 35% (6/17) in pain scale, and 29% (5/17) in role 
limitations-emotional.
Statistically significant changes from baseline occurred 
at both 1-month and 1-year assessments for the RAND 
SF-36 role limitations-physical (p < 0.002 and p < 0.03, 
respectively) and health change (p < 0.004 and p < 0.02, 
respectively) categories. A statistically significant change 
occurred from baseline at 1 month in the energy category 
(p < 0.006) and the average score (p < 0.001). Bonferroni 
corrections retained statistically significant differences 
at 1 month in these four categories (p < 0.02). Most cat-
egories in the RAND SF-36 showed improvement over 
the baseline at 1 month and 1-year evaluations, with the 
exception of the 1-month physical function score. Most 
categories scored highest at the 1-month evaluation with 
the exception of the physical function category (Fig. 6).
Pre- and post-treatment MRIs from the brain and the 
cervical spinal cord were reviewed qualitatively for every 
subject. MRI was unavailable at the 1-year follow-up for 
two subjects. Not all subjects had the second MRI taken 
at exactly 1  year after treatment; there was some varia-
tion in completion of the second MRI, up to 4  months 
after the 1-year mark. No common themes were detected 
regarding number of lesions or disappearance of lesions. 
Of the 18 subjects that did complete MRI both at base-
line and at the 1-year follow-up, 15 (83.3%) showed no 
disease progression or no new or active lesions. Two 
subjects (11.1%) showed progression in their lesions. 
One patient (5.6%) showed near complete resolution 
of the plaques in the brain, in previously noted areas of 
Fig. 2 Scripps Neurological Rating Scale (SNRS) scores. Bladder, bowel and sexual dysfunction SNRS scores. The normal score is 0. A higher score on 
the SNRS indicates a higher level of neurological functioning, with possible scores ranging from − 10 to 100. N = 20 at 1 month (same as baseline), 
N = 17 at 1 year. Statistically significant changes between time points are indicated with their p-values
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abnormal signal intensity consistent with demyelinating 
disease (Fig. 7).
Discussion
The demographics of this study correspond to those of 
an expected MS population, where women are typically 
affected twice as frequently as men, and most patients are 
diagnosed between 20 and 40 years of age [26–29].
No Serious Adverse Events occurred in the study. One 
single Adverse Event (AE), headache, was noted as prob-
ably related to treatment. Of the AEs denoted as possi-
bly related to treatment, most were headache or fatigue. 
Headache is a known complaint noted to occur during or 
just after MSC infusions, most of which quickly resolve 
[30]. Additionally, Foley et al demonstrated that patients 
with MS commonly experience headache [31]. Thus, 
Fig. 3 Nine Hole Peg Test (9HPT) for non-dominant hand. Best (a) and average (b) times for non-dominant hand. The 9HPT is an evaluation of arm/
upper extremity functionality or disability. A reduction in the test time from the reference time point signifies an improvement of upper extremity 
function. N = 20 at 1 month (same as baseline), N = 19 at 1 year. Statistically significant changes between time points are indicated with their 
p-values. Error bars represent standard deviations
Table 4 25-Foot Walk Test times
Trial 1—average time Trial 2—average time Overall mean time Average minimum time
Baseline 17.43 (N = 18) 17.51 (N = 18) 17.47 (N = 18) 15.85 (N = 18)
1 month 29.19 (N = 18) 11.50 (N = 13) 28.63 (N = 18) 28.01 (N = 18)
1 year 16.18 (N = 15) 13.29 (N = 13) 15.70 (N = 15) 14.71 (N = 15)
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headache is not unexpected at the time of or just after 
UCMSC infusions. Similarly, fatigue is one of the most 
common complaints [32]. Fatigue appears in all ages and 
phenotypes of MS [33–35] and is a primary determinant 
of poor QOL [35], affecting both physical and mental 
components independent of disability level [34]. Thus, 
although fatigue is a possibly related AE in this study, it is 
also a very common disability symptom of MS.
Enrolled subjects experienced an improvement in their 
symptoms, which was most notable at 1  month after 
treatment, and was sustained at 1  year in some cases 
(Table  6). The potential durable benefit of UCMSC at 
1 month, and sustained in some measures to 1 year, is in 
stark contrast to current MS drug therapies, which are 
required to be taken daily or weekly [36]. In addition, MS 
drugs are known to carry side effects [37] not seen after 
UCMSC infusions up to 1-year after treatment.
Previous studies using MSC treatment for MS have 
reported improvements in EDSS scores [19, 22, 23, 38, 
39]. In our case, the statistically significant (p < 0.03) 
change in EDSS mean scores from baseline to 1  month 
reflects a change in disability category, which could trans-
late into an improved ability to walk and work a full day 
with minimal, if any, assistance. Although other catego-
ries showed worsening typical of disease progression, the 
bladder/bowel/sexual dysfunction category of the SNRS 
showed statistically significant improvement at 1 month 
(p < 0.05). This finding may be encouraging in that up to 
Fig. 4 25 Foot Walk Test (25FWT) 2nd trial scores. Subjects were asked to perform two trials of a 25-Foot Walk. Not all subjects completed both 
trials, or performed these tests at all time points. In this figure N = 12, and statistically significant changes between time points are indicated with 
their p-values. Error bars represent standard deviations
Fig. 5 RAND SF-36 quality of life scores compared to baseline. Scores for the RAND SF-36 question capture health change. Scores were compared 
with baseline at the 1-month and 1-year visits. N = 20 at 1 month (same as baseline), N = 17 at 1 year
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60% of patients with MS report sexual dysfunction prob-
lems [40] while over 50% experience bowel dysfunction 
and up to 75% will report bladder dysfunction [41].
Changes to ambulatory status from baseline classifi-
cations were noteworthy in this study for the 25FWT. 
Increasing disability (e.g., going from unassisted walk-
ing to a cane) is a typical disease progression in the 
MS population in general, but the reverse would not 
be expected. However, subjects in our study improved 
from wheelchair status to using a walker, and from 
walker status to requiring no assistance.
In general, QOL for patients with MS is diminished by 
physical, emotional, and cognitive symptoms and comor-
bidities [33, 42]. However, subjects enrolled in this study 
reported consistent improvements in their RAND 36 SF 
QOL in these areas, particularly at the 1-month evaluation 
(p < 0.001). Most categories improved at 1 month, and then 
slipped slightly at the 1 year evaluation period while still 
remaining improved over baseline, suggesting that treat-
ment frequency greater than once annually could further 
improve the treatment subject’s QOL outlook.
Most subjects (83.3%) showed no disease progression 
or new lesions in their MRIs. The near complete resolu-
tion of the plaques of the brain in one patient (Fig. 7) is 
a particularly encouraging finding that should be further 
investigated by comparing it to similar MS cohorts in a 
standardized time period.
The small sample size is the most significant limitation 
of this study in that it may impact the statistical signifi-
cance of the results. When subjects were lost to follow-
up, the sample size was reduced; due to the nature of 
certain tests used to measure efficacy signals, failing to 
complete one part of the test often invalidated obtaining 
an average for the score. While this issue could have been 
avoided with larger recruitment numbers, we are still in 
the lower threshold of the 20–80 subjects recommended 
Table 5 RAND SF-36 changes in scores
a Differences between baseline and 1-month and 1-year scores statistically significant (p < 0.03)
b Differences between baseline and 1-month scores statistically significant (p < 0.001)
Baseline to 1 month (N = 20) Baseline to 1 year (N = 17)
Better Same Worse Better Same Worse
Physical functioning 7 (35%) 4 (20%) 9 (45%) 10 (59%) 1 (6%) 6 (35%)
Role limitations—physicala 13 (65%) 6 (30%) 1 (5%) 11 (65%) 4 (24%) 2 (12%)
Role limitations—emotional 7 (35%) 10 (50%) 3 (15%) 5 (29%) 9 (53%) 3 (18%)
Energy/fatigueb 16 (80%) 1 (5%) 3 (15%) 11 (65%) 0 (0%) 6 (35%)
Emotional well-being 13 (65%) 2 (10%) 5 (25%) 10 (59%) 2 (12%) 5 (29%)
Social functioning 12 (60%) 2 (10%) 6 (30%) 8 (47%) 1 (6%) 8 (47%)
Pain 9 (45%) 5 (25%) 6 (30%) 6 (35%) 8 (47%) 3 (18%)
General health 11 (55%) 1 (5%) 8 (40%) 9 (53%) 2 (12%) 6 (35%)
Health  changea 13 (65%) 6 (30%) 1 (5%) 11 (65%) 4 (24%) 2 (12%)
Fig. 6 Changes in RAND SF-36 component scores. Changes in scores for all the RAND SF-36 categories. Asterisk denotes statistically significant 
changes (p < 0.05) both at 1 month and 1 year post-treatment; degree denotes statistically significant change (p < 0.05) at 1 month post-treatment
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by FDA for early trials. Additionally, subjects with certain 
forms of MS may be less likely to develop new lesions, 
which may impact the findings of the reported MRI 
results. As this was primarily a safety and proof of con-
cept trial, we did not require subjects to stop their usual 
medications, which could have a confounding impact on 
our findings. Poor medication adherence is frequently 
seen among patients with MS (usually because of cost, 
perceived lack of efficacy, or adverse effects) [43]; in our 
sample, 25% were not taking any MS-specific medication 
at the start of treatment. However, it is noteworthy that a 
further 20% felt well enough to reduce their intake. In any 
case, efficacy of UCMSC therapy for MS should be con-
firmed with larger, controlled, randomized trials.
Conclusions
We have shown that the intravenous infusion of UCMSC 
over several days is safe in subjects with MS. Addition-
ally, UCMSC infusions may hold benefits, since this small 
study group saw improvement in bladder, bowel, and 
sexual dysfunction, walking, upper extremity physical 
Fig. 7 Changes in magnetic resonance imaging (MRI) before and after treatment. Gadolinium-enhanced MRI scans of the brain for one subject 
before (a and c) and after (b and d) treatment. Lesions of interest are indicated by a white arrow. b Interval resolution of a lesion in the right frontal 
juxtacortical white matter (a). d Interval resolution of a lesion in the right periatrial white matter (c). Names and other personal information have 
been edited out of the images
Table 6 Summary of efficacy assessment scores
* p < 0.05 when compared to baseline; *** p < 0.001 when compared to baseline
Test Baseline 1 month 1 year
EDSS mean scores 5.2 4.8* 4.5*
SNRS bladder/bowel/sexual dys-
function score (normal = 0)
− 4.7 − 2.7* − 3.1
Nine Hole Peg Test—non-domi-
nant hand average scores
35.1 30.2* 34.1
25-foot walk (second trial) times 17.5 11.5* 13.3
RAND SF-36 average scale 53.5 68.3*** 63.5
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function, energy and fatigue, general perspective of a 
positive health change and improved quality of life, and 
MRI lesions. More clinical studies, particularly with a 
larger cohort, are needed to substantiate the specific ben-
efits of UCMSC infusion as a potential MS therapy.
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